A novel genomic fusion breakpoint (GFB)-based MRD monitoring approach demonstrates superior sensitivity and specificity in pediatric ALL, addressing limitations of current IG/TCR-based methods, particularly in ETV6::RUNX1- and MEF2D-rearranged subtypes.